USPTO serial 98666654
EMPOWER PHARMA
Reviewed by CopyMark Law Group
Status 601
- Filing date
- Status date
- Registration date
- —
- Examiner
- —
- Law office
- —
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with EMPOWER PHARMA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
John A. Yates
John A. Yates Patterson + Sheridan, LLP24 Greenway PlazaSuite 1600Houston, TX 77046Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for weight management, hormone replacement therapy, intravenous therapy, intravenous nutrition, injectable therapy, dietary nutrition, mental health, skin care, sexual dysfunction, fertility, men's health, women's health, and gender-affirming care; pharmaceutical preparations for the prevention, reduction, and treatment of cardiovascular, lymphatic, respiratory, pulmonary, neurological, renal, gastrointestinal, musculoskeletal, dermatological, allergic, inflammatory, autoimmune, gynecological, genetic, longevity, metabolic, and pain conditions; disinfecting wipes; and sanitizing wipes. | ACTIVE | — |
| 010 | Medical syringes; disposable syringes; injection syringes, namely, syringe barrels and luer lock syringe barrels; injection needles for medical use; trocars; and containers especially adapted for the disposal of medical instruments and syringes | ACTIVE | — |
| 040 | Custom manufacture of pharmaceuticals; contract manufacturing of pharmaceuticals; contract manufacturing for others; contract manufacturing for others in the field of pharmacology, microbiology, toxicology, and biotechnology | ACTIVE | — |
| 042 | Pharmaceutical drug development services and contract pharmaceutical drug development services; Research and development services of pharmaceutical products and preparations; Research and development services of pharmaceutical products and preparations for others; Conducting research, formulation development, clinical trials, commercial production, packaging, supply chain management, quality assurance, regulatory compliance, and post-marketing product support for others in the pharmaceutical industry in the field of pharmaceuticals; Laboratory research services and contract research services, namely, analytical and microbiological testing for others in the pharmaceutical industry; Laboratory analysis for others in the field of pharmaceuticals; Laboratory services in the fields of pharmacology, microbiology, toxicology, and biotechnology; Testing and analysis of pharmaceuticals per industry standards and for compliance with the requirements of the United States Pharmacopeia regulatory requirements; Quality control testing for others in the pharmaceutical industry; Quality management services, namely, quality evaluation and analysis, quality assurance, and quality control, in the fields of pharmacology, microbiology, toxicology, and biotechnology; Testing of pharmaceutical raw materials to determine conformity with established regulatory standards | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jan 24, 2025 | MAB1 | ABANDONMENT NOTICE E-MAILED - EXPRESS ABANDONMENT | — |
| Jan 24, 2025 | ABN1 | ABANDONMENT - EXPRESS MAILED | — |
| Jan 23, 2025 | EXAR | TEAS EXPRESS ABANDONMENT RECEIVED | — |
| Jan 12, 2025 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Jan 12, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 25, 2024 | NWAP | NEW APPLICATION ENTERED | — |